Perioperative Pembro or EV + Pembro in Cisplatin-Ineligible #MIBC: Ad Hoc Analysis from KEYNOTE-905. Presented by Anders Ullén, MD. #ESMO26 written coverage by @chavarriagaj @PSH_U

UroToday.com· @urotoday · X·2026-10-24 03:00· 2 days agoScore70

Body · original

Perioperative Pembro or EV + Pembro in Cisplatin-Ineligible #MIBC: Ad Hoc Analysis from KEYNOTE-905. Presented by Anders Ullén, MD. #ESMO26 written coverage by @chavarriagaj @PSH_Urology > https://bit.ly/4ieyBr7 #BladderCancer #Immunotherapy

292 views · 4 likes · 4 reposts · 0 replies

Conference abstracts

4733Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905

https://esmocongress.esmo.org

NCT03924895NCT03924895matched by - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

https://esmocongress.esmo.org

Source: UroToday.com · x.com